SG11202010792TA - Improved pharmaceutical formulations - Google Patents
Improved pharmaceutical formulationsInfo
- Publication number
- SG11202010792TA SG11202010792TA SG11202010792TA SG11202010792TA SG11202010792TA SG 11202010792T A SG11202010792T A SG 11202010792TA SG 11202010792T A SG11202010792T A SG 11202010792TA SG 11202010792T A SG11202010792T A SG 11202010792TA SG 11202010792T A SG11202010792T A SG 11202010792TA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical formulations
- improved pharmaceutical
- improved
- formulations
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201811016594 | 2018-05-02 | ||
PCT/EP2019/060605 WO2019211159A1 (en) | 2018-05-02 | 2019-04-25 | Improved pharmaceutical formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202010792TA true SG11202010792TA (en) | 2020-11-27 |
Family
ID=66290450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202010792TA SG11202010792TA (en) | 2018-05-02 | 2019-04-25 | Improved pharmaceutical formulations |
Country Status (14)
Country | Link |
---|---|
US (2) | US11648201B2 (en) |
EP (1) | EP3787596A1 (en) |
JP (1) | JP2021522299A (en) |
KR (1) | KR20210005224A (en) |
CN (1) | CN112040929A (en) |
BR (1) | BR112020021852A2 (en) |
CA (1) | CA3099055A1 (en) |
CL (1) | CL2020002766A1 (en) |
CO (1) | CO2020013679A2 (en) |
MX (2) | MX2020011541A (en) |
PH (1) | PH12020551798A1 (en) |
SG (1) | SG11202010792TA (en) |
TW (1) | TW202002953A (en) |
WO (1) | WO2019211159A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3174693A1 (en) * | 2020-05-08 | 2021-11-11 | Fertin Pharma A/S | Flowpack for oral delivery of active ingredients |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2716624B1 (en) * | 1994-02-25 | 1996-05-03 | Jouveinal Lab | Low calorie laxative jelly based on liquid paraffin oil and lactulose, its preparation process. |
ITFI970184A1 (en) | 1997-07-30 | 1999-01-30 | Menarini Farma Ind | PHARMACEUTICAL COMPOSITIONS CONTAINING VITAMIN D AND CALCIUM, THEIR PREPARATION AND THERAPEUTIC USE |
RU2175554C2 (en) | 1999-03-30 | 2001-11-10 | Пермское научно-производственное объединение "Биомед" | Tableted interferon preparation for oral use |
EP1235561A2 (en) * | 1999-11-30 | 2002-09-04 | Panacea Biotec Limited | Fast dissolving composition with prolonged sweet taste |
WO2006020534A2 (en) * | 2004-08-09 | 2006-02-23 | Dr. Reddy's Laboratories Ltd. | Stabilized desloratadine composition |
DE102005009240A1 (en) | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Dosage forms with improved pharmacokinetic properties |
KR20070121786A (en) * | 2005-03-23 | 2007-12-27 | 엘란 파마 인터내셔널 리미티드 | Nanoparticulate corticosteroid and antihistamine formulations |
US7611739B2 (en) * | 2006-01-06 | 2009-11-03 | Amerilab Technologies, Inc. | Method of using guava extract and composition including guava extract |
US20090004270A1 (en) * | 2006-01-06 | 2009-01-01 | Amerilab Technologies, Inc. | Method of using guava extract |
EP1970053A1 (en) | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
US20100310668A1 (en) * | 2008-02-13 | 2010-12-09 | Ratiopharm Gmbh | Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide |
RU2497503C9 (en) * | 2008-03-10 | 2014-09-20 | Байер Конзюмер Кер АГ | Nice to taste solid composition containing de-acidifier and salivation stimulator |
CN103550214A (en) * | 2008-03-26 | 2014-02-05 | 塔罗制药北美有限公司 | Stabilizing lipid compositions for oral pharmaceutical agents |
TR200806298A2 (en) | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Pharmaceutical formulation |
RU2454221C2 (en) | 2010-07-06 | 2012-06-27 | Общество с ограниченной ответственностью "Завод Медсинтез" | Method for preparing lyophilised antiviral agent |
EP2468258A1 (en) * | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
PE20140255A1 (en) | 2011-01-17 | 2014-03-11 | Takeda Pharmaceutical | DISPERSIBLE TABLET IN ORAL FORM |
WO2013077829A1 (en) * | 2011-11-21 | 2013-05-30 | Mahmut Bilgic | Water-soluble pharmaceutical granules |
CA2873572C (en) * | 2012-05-16 | 2021-07-06 | Mewa Singh | Pharmaceutical compositions for the delivery of substantially water-insoluble drugs |
MX2015016675A (en) | 2013-06-04 | 2016-07-15 | Vyome Biosciences Pvt Ltd | Coated particles and compositions comprising same. |
-
2019
- 2019-04-25 JP JP2020561663A patent/JP2021522299A/en active Pending
- 2019-04-25 EP EP19719868.2A patent/EP3787596A1/en active Pending
- 2019-04-25 MX MX2020011541A patent/MX2020011541A/en unknown
- 2019-04-25 BR BR112020021852-9A patent/BR112020021852A2/en unknown
- 2019-04-25 WO PCT/EP2019/060605 patent/WO2019211159A1/en unknown
- 2019-04-25 CN CN201980028696.XA patent/CN112040929A/en active Pending
- 2019-04-25 KR KR1020207034567A patent/KR20210005224A/en unknown
- 2019-04-25 US US17/051,732 patent/US11648201B2/en active Active
- 2019-04-25 CA CA3099055A patent/CA3099055A1/en active Pending
- 2019-04-25 SG SG11202010792TA patent/SG11202010792TA/en unknown
- 2019-04-30 TW TW108115070A patent/TW202002953A/en unknown
-
2020
- 2020-10-26 CL CL2020002766A patent/CL2020002766A1/en unknown
- 2020-10-28 PH PH12020551798A patent/PH12020551798A1/en unknown
- 2020-10-29 MX MX2023008569A patent/MX2023008569A/en unknown
- 2020-10-30 CO CONC2020/0013679A patent/CO2020013679A2/en unknown
-
2023
- 2023-03-30 US US18/128,922 patent/US20230346704A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210005224A (en) | 2021-01-13 |
TW202002953A (en) | 2020-01-16 |
WO2019211159A1 (en) | 2019-11-07 |
EP3787596A1 (en) | 2021-03-10 |
CO2020013679A2 (en) | 2021-03-19 |
CL2020002766A1 (en) | 2021-02-19 |
US20210236426A1 (en) | 2021-08-05 |
BR112020021852A2 (en) | 2021-02-23 |
CN112040929A (en) | 2020-12-04 |
MX2023008569A (en) | 2023-08-08 |
US11648201B2 (en) | 2023-05-16 |
PH12020551798A1 (en) | 2021-06-14 |
US20230346704A1 (en) | 2023-11-02 |
JP2021522299A (en) | 2021-08-30 |
MX2020011541A (en) | 2020-11-24 |
CA3099055A1 (en) | 2019-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2569961B (en) | Pharmaceutical | |
GB2572126B (en) | Pharmaceutical | |
GB2572125B (en) | Pharmaceutical | |
GB201807942D0 (en) | Pharmaceutical formulation | |
ZA201903101B (en) | Pharmaceutical formulations | |
ZA202006570B (en) | Pharmaceutical formulations | |
IL262745A (en) | Improved drug formulations | |
IL285674A (en) | Pharmaceutical formulations | |
GB201804548D0 (en) | Pharmaceutical compositions | |
ZA202102871B (en) | Pharmaceutical formulation | |
SG11202010124SA (en) | Stable pharmaceutical formulation | |
IL278927A (en) | Pharmaceutical formulation | |
IL283450A (en) | Capsule formulations | |
IL282343A (en) | Aqueous pharmaceutical formulations | |
GB201807053D0 (en) | Pharmaceutical composition | |
SG11202103374TA (en) | Pharmaceutical composition | |
GB201912505D0 (en) | Pharmaceutical formulation | |
GB201808571D0 (en) | Pharmaceutical compositions | |
SG11202010792TA (en) | Improved pharmaceutical formulations | |
ZA202006346B (en) | Pharmaceutical preparation | |
IL271908A (en) | Hypercompressed pharmaceutical formulations | |
GB201906473D0 (en) | Pharmaceutical formulation | |
EP3746080A4 (en) | Pharmaceutical formulations | |
EP3706731A4 (en) | Improved drug formulations | |
GB201808567D0 (en) | Pharmaceutical compositions |